MBX Biosciences (MBX) Change in Acquisitions & Divestments (2023 - 2026)
MBX Biosciences has reported Change in Acquisitions & Divestments over the past 4 years, most recently at $57.5 million for Q1 2026.
- Quarterly results put Change in Acquisitions & Divestments at $57.5 million for Q1 2026, up 0.61% from a year ago — trailing twelve months through Mar 2026 was $268.2 million (up 138.1% YoY), and the annual figure for FY2025 was $267.9 million, up 235.89%.
- Change in Acquisitions & Divestments reached $57.5 million in Q1 2026 per MBX's latest filing, down from $76.2 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $76.2 million in Q4 2025 and bottomed at $5.0 million in Q4 2023.
- Median Change in Acquisitions & Divestments over the past 4 years was $42.1 million (2024), compared with a mean of $41.0 million.
- The largest annual shift saw Change in Acquisitions & Divestments soared 786.33% in 2025 before it grew 0.61% in 2026.
- Over 4 years, Change in Acquisitions & Divestments stood at $5.0 million in 2023, then surged by 305.0% to $20.2 million in 2024, then skyrocketed by 276.54% to $76.2 million in 2025, then fell by 24.59% to $57.5 million in 2026.
- Business Quant data shows Change in Acquisitions & Divestments for MBX at $57.5 million in Q1 2026, $76.2 million in Q4 2025, and $61.4 million in Q3 2025.